GENAGON THERAPEUTICS AB has a total of 28 patent applications. It increased the IP activity by 80.0%. Its first patent ever was published in 2015. It filed its patents most often in United Kingdom, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are ALLAKOS INC, CYTOMX THERAPEUTICS INC and TRION PHARMA GMBH.
# | Country | Total Patents | |
---|---|---|---|
#1 | United Kingdom | 11 | |
#2 | WIPO (World Intellectual Property Organization) | 5 | |
#3 | EPO (European Patent Office) | 4 | |
#4 | United States | 4 | |
#5 | Australia | 1 | |
#6 | Canada | 1 | |
#7 | China | 1 | |
#8 | Republic of Korea | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Climate change adaptation technologies | |
#5 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Blokzijl Olof Andries | 17 |
#2 | Fredriksson Johan Erik Simon | 17 |
#3 | Mangsbo Sara Maria | 1 |
Publication | Filing date | Title |
---|---|---|
GB202012736D0 | Polypeptides | |
GB202012731D0 | Therapeutic agents | |
GB201911708D0 | Polypeptides | |
GB201911712D0 | Therapeutic agents | |
GB201811753D0 | Therapeutic agents | |
GB201811755D0 | Polypeptides | |
GB201804531D0 | Antigen binding proteins | |
GB201700553D0 | Therapeutic agents | |
GB201700567D0 | Therapeutic agents | |
GB201615844D0 | Agents for use in therapy | |
GB201512733D0 | Therapeutic agents for treating conditions associated with elevated GDF15 |